<p style="text-align: left;"> </p> <p><strong><span data-contrast="auto">About Parabilis Medicines</span></strong><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":0,"335559740":259}"> </span></p> <p><span data-contrast="none">Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit </span><a href="https://url.us.m.mimecastprotect.com/s/gYX5CkRVZgtkknDEuVhmcGHXzh?domain=parabilismed.com/"><span data-contrast="none"><span data-ccp-charstyle="Hyperlink">www.parabilismed.com</span></span></a><span data-contrast="none"> or follow us on </span><a href="https://url.us.m.mimecastprotect.com/s/7qd3ClYV50H11oWrFyinczUQak?domain=linkedin.com"><span data-contrast="none"><span data-ccp-charstyle="Hyperlink">LinkedIn</span></span></a><span data-contrast="none">.</span><span data-ccp-props="{"335551550":6,"335551620":6}"> </span></p> <p><strong>What’s the opportunity?</strong></p> <p>We are seeking a Senior Scientist, Clinical Biomarkers to execute biomarker strategies that carry our oncology programs from pre-IND through Phase 1/2 clinical trials. In this role, you will translate preclinical biomarker findings into clinically feasible strategies, select and qualify fit-for-purpose assays, and drive hypothesis-driven data analysis and interpretation to inform patient selection, mechanism of action, and response monitoring. You will collaborate closely with Data Science, Biology, Clinical Science, Clinical Operations, Clinical Pharmacology, to translate biological insights into actionable clinical decisions and external engagement (e.g., with investigators and partners).</p> <p>This is an individual-contributor role well suited to a scientist who is ready to apply their preclinical translational background to clinical biomarker work, with support from senior team members and cross-functional partners including Clinical Science, Clinical Operations, and Clinical Pharmacology. In this role, you will have the opportunity to shape biomarker strategy across a growing oncology pipeline.</p> <p><strong>Key Responsibilities</strong></p> <ul> <li>Capture key biomarkers identified in preclinical studies and assess their feasibility for clinical translation, from pre-IND through Phase 1/2 programs</li> <li>Develop or qualify and implement fit-for-purpose clinical biomarker assays and vendors, setting expectations for anticipated data readouts, interpretation, and delivery timelines</li> <li>Conduct hypothesis-driven analysis, interpretation, and presentation of clinical biomarker data in support of clinical decision-making and external engagement</li> <li>Establish and maintain strong collaborative relationships with Data Science and Biology colleagues to perform exploratory biomarker analysis and support novel biomarker identification</li> <li>Partner with Clinical Science, Clinical Operations, and Clinical Pharmacology to embed biomarker strategy into protocol design and study execution</li> <li>Track and interpret emerging biomarker literature and competitive landscape to inform biomarker strategy</li> </ul> <p><strong>What you’ll need to be successful:</strong></p> <ul> <li>Ph.D. in Cancer Biology, Immunology, or a closely related field</li> <li>5+ years of total experience with at least 2+ years of industry experience in biomarker research spanning pre-IND through Phase 1/2 clinical programs</li> <li>Prior experience in preclinical oncology translational research</li> <li>In-depth knowledge of fit-for-purpose assay technologies and their implementation in clinical studies</li> <li>Direct experience with established and evolving biomarker assay technologies (e.g., spatial omics, multiplex immunoassays, NGS, IHC, flow cytometry, ctDNA/liquid biopsy)</li> <li>Experience in clinical spatial omics assay design, execution, and downstream bioinformatics analysis (e.g., cell segmentation, spatial clustering), in collaboration with Data Science, is highly preferred</li> <li>Proven track record of delivering impactful clinical translational data in close collaboration, preferably in an industry setting</li> <li>Demonstrated ability to interpret complex biomarker datasets and translate findings into clinical/scientific recommendations</li> <li>Excellent written and verbal communication skills; experience